AIM: To estimate incidence of stage III melanoma using the American Joint Committee on Cancer (AJCC) staging, 7th and 8th edition. PATIENTS & METHODS: The SEER US cancer registry was analyzed (2010-2014). AJCC7 stages were recorded in the data; AJCC8 stages were inferred. RESULTS: Of 106,195 melanoma patients, 7669 and 7342 had stage III melanoma by AJCC7 and AJCC8, respectively (95% overlap). Nearly 30% of patients with AJCC7 stage III melanoma were reclassified in a higher stage III group by AJCC8 versus 7% in lower stage group. Regardless of the AJCC edition, incidence of stage III melanoma has increased from 2010 to 2014 both overall and within each stage III group. CONCLUSION: Providing appropriate management to this growing population of high-risk patients is a priority.
AIM: To estimate incidence of stage III melanoma using the American Joint Committee on Cancer (AJCC) staging, 7th and 8th edition. PATIENTS & METHODS: The SEER US cancer registry was analyzed (2010-2014). AJCC7 stages were recorded in the data; AJCC8 stages were inferred. RESULTS: Of 106,195 melanomapatients, 7669 and 7342 had stage III melanoma by AJCC7 and AJCC8, respectively (95% overlap). Nearly 30% of patients with AJCC7 stage III melanoma were reclassified in a higher stage III group by AJCC8 versus 7% in lower stage group. Regardless of the AJCC edition, incidence of stage III melanoma has increased from 2010 to 2014 both overall and within each stage III group. CONCLUSION: Providing appropriate management to this growing population of high-risk patients is a priority.
Authors: Paolo A Ascierto; Paolo Bruzzi; Alexander Eggermont; Omid Hamid; Hussein A Tawbi; Alexander van Akkooi; Alessandro Testori; Corrado Caracò; Igor Puzanov; Francesco Perrone Journal: J Transl Med Date: 2019-05-10 Impact factor: 5.531
Authors: Ahmad A Tarhini; Sandra J Lee; Aik-Choon Tan; Issam M El Naqa; F Stephen Hodi; Lisa H Butterfield; William A LaFramboise; Walter J Storkus; Arivarasan D Karunamurthy; Jose R Conejo-Garcia; Patrick Hwu; Howard Streicher; Vernon K Sondak; John M Kirkwood Journal: J Immunother Cancer Date: 2022-01 Impact factor: 12.469